Empowering Patients: A Holistic Approach to Supporting Mental Health in Breast Cancer Survivors
Ngày đăng: 07-02-2024 |
Ngày cập nhật: 07-02-2024
Market Overview:
Global Breast Cancer Market Size is projected to grow a staggering CAGR of 9.2% during 2023 and 2032. The Breast Cancer Market encompasses a broad spectrum of pharmaceuticals, medical devices, and diagnostic tools aimed at the prevention, diagnosis, treatment, and management of breast cancer. Breast cancer is one of the most common cancer types globally, affecting millions of individuals each year, with a significant impact on public health and healthcare systems.
Hormone therapy, on the other hand, is particularly effective in treating hormone receptor-positive breast cancer, which accounts for a significant proportion of breast cancer cases. This therapy works by blocking the production or action of hormones, such as estrogen and progesterone, which can fuel the growth of hormone receptor-positive breast cancer cells. By disrupting hormone signaling pathways, hormone therapy helps slow or stop the growth of cancer cells, thereby improving patient prognosis and reducing the risk of disease progression.
The market for breast cancer therapies and technologies is driven by several factors. Firstly, the increasing incidence of breast cancer worldwide, coupled with rising awareness and early detection efforts, has led to a growing demand for effective treatment options. Additionally, advancements in medical research, genomics, and personalized medicine have led to the development of targeted therapies and immunotherapies, offering improved outcomes and reduced side effects for patients.
Key segments within the breast cancer market include chemotherapy, hormonal therapy, targeted therapy, immunotherapy, and surgical interventions such as lumpectomy and mastectomy. These treatment modalities are often used in combination or sequentially, depending on the stage and subtype of breast cancer, as well as individual patient factors.
Diagnostic tools and imaging technologies also play a crucial role in the breast cancer market, enabling early detection, accurate staging, and monitoring of treatment response. Mammography, ultrasound, magnetic resonance imaging (MRI), and molecular imaging techniques are commonly used for breast cancer screening and diagnosis.
The Key Competitors
Global Breast Cancer Market Players are: Pfizer (US), Novartis AG (Switzerland), Oncogenex (US), Apthera Inc. (UK), BioNumerik Pharmaceuticals (US), Oncothyreon Inc. (US), Astellas (Japan), Bipar Sciences (US), Puma Biotechnology (US), Sanofi S.A. (US), Eli Lilly and Company (US), AstraZeneca (UK), F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline (UK), Genentech (US), Teva Pharmaceutical Industries (Israel), Sun Pharmaceutical Industries Ltd (India), Accord Healthcare, Inc. (India), Gilead Sciences, Inc. (US), Bristol-Myers Squibb company (US), Actavis, Inc. (US), Hospira, Inc. (US), and Bayer AG (Germany).
Breast Cancer Market – Competitive Analysis
Characterized by the presence of several major players, having international recognition; the global market of Breast Cancer appears to be highly fragmented and competitive. Marketers compete based upon price and brand reinforcement. Well established players incorporate acquisition, collaboration, partnership, expansion, and technology launch in order to gain competitive advantage in this market and to maintain their market position.
Breast cancer is the most commonly occurring segment of cancer in women worldwide. The recent reports on cancer confirm the registration of 1.7 million cases of breast cancer. Women populace in the developed countries like U.S, U.K, and Australia are more prone to the breast cancer than in the developing countries. Factors such as lifestyle, age, heredity and also genetic mutations (abnormal changes) are responsible for developing a breast cancer. The high incidence rate worldwide is becoming a major concern and the pharmaceutical companies are increasingly investing in research on breast cancer.
Breast Cancer Market – Segments
The Breast Cancer Market insight is segmented in to 4 key dynamics for the convenience of the report and enhanced understanding;
Segmentation by Types: Comprises Invasive Ductal Carcinoma, Invasive Lobular Carcinoma and other.
Segmentation by Treatment : Comprises Chemotherapy (Antimetabolites, Anthracyclines, Taxanes & Alkylating Agents), Surgery & Radiation Therapy, Targeted Therapy (Tyrosine Kinase Inhibitors &Monoclonal Antibodies), Biologic Therapy, Hormone Therapy (selective estrogen-receptor modulators (SERMs), aromatase inhibitors) and other.
Segmentation by End Users: Comprises Hospital Pharmacies, Private Pharmacies and others.
Segmentation by Regions: Comprises Geographical regions - North America, Europe, APAC and Rest of the World.
Chemotherapy accounts for the largest share of the market; i.e. 45%.
Breast Cancer Market – Regional Analysis
On regional basis, global breast cancer market is dominated by America. Changing lifestyle and increasing prevalence of breast cancer in America has driven the growth rate of breast cancer. America breast cancer market is followed by Europe. Technological advances, increased life expectancy and healthcare expenditure of people is responsible for the growth of this market in America and Europe. Asia Pacific is expecting a fastest growth for the market.
For more information, Please Visit us @ Market Research Future
Global Breast Cancer Market Size is projected to grow a staggering CAGR of 9.2% during 2023 and 2032. The Breast Cancer Market encompasses a broad spectrum of pharmaceuticals, medical devices, and diagnostic tools aimed at the prevention, diagnosis, treatment, and management of breast cancer. Breast cancer is one of the most common cancer types globally, affecting millions of individuals each year, with a significant impact on public health and healthcare systems.
Hormone therapy, on the other hand, is particularly effective in treating hormone receptor-positive breast cancer, which accounts for a significant proportion of breast cancer cases. This therapy works by blocking the production or action of hormones, such as estrogen and progesterone, which can fuel the growth of hormone receptor-positive breast cancer cells. By disrupting hormone signaling pathways, hormone therapy helps slow or stop the growth of cancer cells, thereby improving patient prognosis and reducing the risk of disease progression.
The market for breast cancer therapies and technologies is driven by several factors. Firstly, the increasing incidence of breast cancer worldwide, coupled with rising awareness and early detection efforts, has led to a growing demand for effective treatment options. Additionally, advancements in medical research, genomics, and personalized medicine have led to the development of targeted therapies and immunotherapies, offering improved outcomes and reduced side effects for patients.
Key segments within the breast cancer market include chemotherapy, hormonal therapy, targeted therapy, immunotherapy, and surgical interventions such as lumpectomy and mastectomy. These treatment modalities are often used in combination or sequentially, depending on the stage and subtype of breast cancer, as well as individual patient factors.
Diagnostic tools and imaging technologies also play a crucial role in the breast cancer market, enabling early detection, accurate staging, and monitoring of treatment response. Mammography, ultrasound, magnetic resonance imaging (MRI), and molecular imaging techniques are commonly used for breast cancer screening and diagnosis.
The Key Competitors
Global Breast Cancer Market Players are: Pfizer (US), Novartis AG (Switzerland), Oncogenex (US), Apthera Inc. (UK), BioNumerik Pharmaceuticals (US), Oncothyreon Inc. (US), Astellas (Japan), Bipar Sciences (US), Puma Biotechnology (US), Sanofi S.A. (US), Eli Lilly and Company (US), AstraZeneca (UK), F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline (UK), Genentech (US), Teva Pharmaceutical Industries (Israel), Sun Pharmaceutical Industries Ltd (India), Accord Healthcare, Inc. (India), Gilead Sciences, Inc. (US), Bristol-Myers Squibb company (US), Actavis, Inc. (US), Hospira, Inc. (US), and Bayer AG (Germany).
Breast Cancer Market – Competitive Analysis
Characterized by the presence of several major players, having international recognition; the global market of Breast Cancer appears to be highly fragmented and competitive. Marketers compete based upon price and brand reinforcement. Well established players incorporate acquisition, collaboration, partnership, expansion, and technology launch in order to gain competitive advantage in this market and to maintain their market position.
Breast cancer is the most commonly occurring segment of cancer in women worldwide. The recent reports on cancer confirm the registration of 1.7 million cases of breast cancer. Women populace in the developed countries like U.S, U.K, and Australia are more prone to the breast cancer than in the developing countries. Factors such as lifestyle, age, heredity and also genetic mutations (abnormal changes) are responsible for developing a breast cancer. The high incidence rate worldwide is becoming a major concern and the pharmaceutical companies are increasingly investing in research on breast cancer.
Breast Cancer Market – Segments
The Breast Cancer Market insight is segmented in to 4 key dynamics for the convenience of the report and enhanced understanding;
Segmentation by Types: Comprises Invasive Ductal Carcinoma, Invasive Lobular Carcinoma and other.
Segmentation by Treatment : Comprises Chemotherapy (Antimetabolites, Anthracyclines, Taxanes & Alkylating Agents), Surgery & Radiation Therapy, Targeted Therapy (Tyrosine Kinase Inhibitors &Monoclonal Antibodies), Biologic Therapy, Hormone Therapy (selective estrogen-receptor modulators (SERMs), aromatase inhibitors) and other.
Segmentation by End Users: Comprises Hospital Pharmacies, Private Pharmacies and others.
Segmentation by Regions: Comprises Geographical regions - North America, Europe, APAC and Rest of the World.
Chemotherapy accounts for the largest share of the market; i.e. 45%.
Breast Cancer Market – Regional Analysis
On regional basis, global breast cancer market is dominated by America. Changing lifestyle and increasing prevalence of breast cancer in America has driven the growth rate of breast cancer. America breast cancer market is followed by Europe. Technological advances, increased life expectancy and healthcare expenditure of people is responsible for the growth of this market in America and Europe. Asia Pacific is expecting a fastest growth for the market.
For more information, Please Visit us @ Market Research Future
